1.
Authors' reply to comment on "Cost-effectiveness analysis of Herpes Zoster vaccination in 50-to 85-year-old immunocompetent Belgian cohorts: a comparison between no vaccination, th...
2.
3.
Cost-effectiveness analysis of herpes zoster vaccination in 50-to 85-year-old immunocompetent Belgian cohorts : a comparison between no vaccination, the adjuvanted subunit vaccine,...